Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Osteoporosis 1Neoplasms 1Musculoskeletal Diseases 1Hyperparathyroidism 1Humoral Hypercalcemia Of Malignancy 1Endocrine System Diseases 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × parathyroid hormone-related peptide (1-36) × Clear all
NCT00580788 2016-02-11

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

University of Pittsburgh

Phase EARLY_PHASE1 Completed
14 enrolled 16 charts
Head & Neck

Humoral Hypercalcemia Of Malignancy, Endocrine System Diseases, Hyperparathyroidism, Musculoskeletal Diseases, Neoplasms, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡